Table 2.
MK-8776-sensitized doxorubicin and paclitaxel in SW620/Ad300 cells.
| Compounds | IC50 ± SD a (μM) (RF b) | |
|---|---|---|
| SW620 | SW620/Ad300 | |
| Doxorubicin | 0.031 ± 0.014 (1.00) | 9.950 ± 2.023 (320.97) |
| + MK-8776 (0.3 μM) | 0.028 ± 0.016 (0.90) | 1.362 ± 0.122 (43.94) * |
| + MK-8776 (1 μM) | 0.035 ± 0.012 (1.13) | 0.426 ± 0.184 (13.74) * |
| + Verapmil (3 μM) | 0.038 ± 0.021 (1.23) | 0.096 ± 0.023 (3.10) * |
| Paclitaxel | 0.091 ± 0.015 (1.00) | 21.19 ± 6.25 (232.86) |
| + MK-8776 (0.3 μM) | 0.076 ± 0.038 (0.84) | 1.784 ± 0.125 (19.60) * |
| + MK-8776 (1 μM) | 0.074 ± 0.003 (0.81) | 0.597 ± 0.566 (6.56) * |
| + Verapamil (3 μM) | 0.113 ± 0.006 (1.24) | 0.639 ± 0.023 (7.03) * |
| Cisplatin | 1.481 ± 0.676 (1.00) | 1.514 ± 0.398 (1.02) |
| + MK-8776 (0.3 μM) | 1.329 ± 0.156 (0.90) | 1.423 ± 0.438 (0.94) |
| + MK-8776 (1 μM) | 1.228 ± 0.181(0.83) | 1.266 ± 0.295 (0.84) |
| + Verapamil (3 μM) | 1.164 ± 0.107 (0.79) | 1.851 ± 0.364 (1.25) |
* p < 0.05 vs. control. a Three independent experiments that were performed in triplicate. b IC50 values of substrates in the resistant cell lines in the presence or absence of MK-8776 or verapamil divided by the IC50 values of substrates in the parental cells without MK-8776 or verapamil.